Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation Trial Investigators.
The Multicenter Automatic Defibrillator Implantation Trial showed that patients at risk for fatal cardiac arrhythmias treated with implanted defibrillators had 50% to 60% fewer deaths than patients treated conventionally.
Clinical trials, such as the Guidant-sponsored Multicenter Automatic Defibrillator Implantation Trial (MADIT) II, have proven the lifesaving benefits of implantable defibrillator therapy for patients at risk for sudden cardiac death.
Previous studies, such as the Multicenter Automatic Defibrillator Implantation Trials (MADIT I and II) and Multicenter Unsustained Tachycardia Trial (MUSTT) have demonstrated the value of ICD therapy in preventing sudden cardiac death, but precisely identifying which patients are at risk of sudden cardiac death remains a challenge for the medical community.
Zareba was in charge of ECG core lab for the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) and currently runs the ECG core lab for the North American ARVD Registry (22 enrolling centers) as well as for the MADIT-CRT (100 enrolling centers).
MADIT II: The Multicenter Automatic Defibrillator Implantation Trial (MADIT) II, sponsored by Guidant, demonstrated that ICD therapy reduced overall mortality by 31 percent in patients who had experienced a previous heart attack and had an ejection fraction of less than or equal to 30 percent.
Clinical trials, such as the Guidant-sponsored Multicenter Automatic Defibrillator Implantation Trial (MADIT) II, have continually proven the lifesaving benefits of implantable defibrillator therapy in various groups of patients considered at risk for sudden cardiac death.
